Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
17 12월 2020 - 11:09PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the launch of its proprietary
Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from
Personalis’ state-of-the-art tumor neoantigen prediction tool,
SHERPA™, with mechanisms of immune evasion to better predict
response to cancer therapy.
NEOPS combines the tumor genomic and immune-related analytics of
the Personalis® NeXT Platform™ to create a composite biomarker that
can be more effective in predicting immunotherapy response than
other, simpler biomarkers. NEOPS leverages Personalis’
recently-launched machine learning-based tool, Systematic HLA
Epitope Ranking Pan Algorithm (SHERPA), which provides more
accurate prediction of neoantigen presentation, a core mechanism in
determining immunotherapy response.
Data presented at the AACR virtual meeting in June demonstrated
that NEOPS significantly outperformed tumor mutational burden in
predicting response to anti-PD-L1 therapy in a cohort of
late-stage, unresectable melanoma patients, highlighting the
potential of composite, neoantigen-based biomarkers to more
effectively stratify responders and non-responders to
immunotherapy. The prevalence of immune evasion events incorporated
into NEOPS suggests that such composite neoantigen-based biomarkers
are potentially applicable to a range of immunotherapies and cancer
types.
“Identifying effective biomarkers for cancer immunotherapy has
proven challenging due to the complex biological mechanisms
underlying patient response. We believe that more sophisticated,
multimodal biomarker models like NEOPS represent the next step in
this pursuit. By combining accurate tumor neoantigen prediction
with mechanisms of immune evasion, we can create a more predictive
model of therapy response,” said Richard Chen, MD, Personalis CSO.
“NEOPS is the first of a new class of composite biomarkers for our
pharma partners to utilize in their clinical trials. In the future,
such biomarkers may be used to inform treatment decisions for
patients.”
NEOPS, SHERPA, and other recent enhancements to the company’s
HLA typing and HLA LOH analytics represent the latest update to the
comprehensive suite of advanced analytical engines of the
Personalis NeXT Platform™. Utilizing an augmented exome and
transcriptome-based approach, NeXT enables the simultaneous
analysis of both a tumor and its immune microenvironment from a
single tumor specimen to explore critical immunotherapy-related
resistance mechanisms and novel composite biomarkers of
response.
About Personalis, Inc.
Personalis, Inc. is a leader in cancer genomics, with a focus on
data, scale, efficiency and quality. Personalis operates one of the
largest sequencing operations globally. In oncology, Personalis is
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis NeXT Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. The Personalis Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit
www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
NEOPS, SHERPA or the Personalis NeXT Platform, the company’s
business opportunities, leadership or growth, or other future
events. Such forward-looking statements involve risks and
uncertainties, including those related to the COVID-19 pandemic,
that could cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements. Factors that could materially affect actual results can
be found in Personalis’ filings with the U.S. Securities and
Exchange Commission, including the company’s most recent reports on
Forms 8-K, 10-K and 10-Q, and include those listed under the
caption “Risk Factors.” Personalis disclaims any obligation to
update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201217005356/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024